Abstract
The purpose of this article is to assess the present knowledge about chronic active (CA) T-cell mediated rejection (TCMR) of a kidney. In the research authors review current Banff diagnostic criteria used in kidney rejection, focus on their possible future evolution, and investigate the role of currently available molecular methods that could be implemented into the diagnostic scheme. Research also points out previously and currently available treatment methods applied to CA TCMR and takes into account possible side effects consequent upon the therapy. Moreover, attention is being paid to the CA TCMR coincidence with other kidney rejection types such as antibody-mediated rejection (ABMR) and its influence on the treatment approach. Authors also mark the possibility of non-HLA antibodies coexistence in patients with CA TCMR and describe its possible resonance on kidney allograft function. Nonetheless, it seems that current knowledge about CA TCMR is not sufficient and requires further investigation.
Funder
The Wroclaw Medical University statutory
Reference43 articles.
1. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology;Loupy;Am. J. Transplant.,2017
2. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell—Mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials;Haas;Am. J. Transplant.,2018
3. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell—And antibody-mediated rejection;Loupy;Am. J. Transplant.,2020
4. Naik, R.H., and Shawar, S.H. (2020). Renal Transplantation Rejection, StatPearls Publishing.
5. Does tubulitis without interstitial inflammation represent borderline acute T cell mediated rejection?;Nankivell;Am. J. Transplant.,2019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献